BRAF and metastatic melanoma: Considering that the assessment of NRAS and BRAF mutations is mandatory for the treatment of metastatic melanoma, the specific antibodies against NRASQ61R and BRAF-V600E proteins are immunohistochemically used to provide supplementary data on tumour heterogeneity [64].